Pleckstrin-2 promotes the progression of colorectal cancer via YTHDF2-mediated TYMS mRNA stability

High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC). Herein, we revealed that pleckstrin-2 (PLEK2) cooperated with YTHDF2 to enhance TYMS mRNA stability in CRC via an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cellular and molecular life sciences : CMLS Ročník 82; číslo 1; s. 284 - 15
Hlavní autoři: Zhou, Qian, Li, Yanxia, Li, Xiaomei, Zhang, Shujing, Wang, Ying, Li, Zhuoran, Wang, Xia, Li, Yuan, Li, Jingxin, Lu, Chunhua, Shen, Yuemao, Zhao, Baobing
Médium: Journal Article
Jazyk:angličtina
Vydáno: Cham Springer International Publishing 19.07.2025
Springer Nature B.V
Springer
Témata:
ISSN:1420-9071, 1420-682X, 1420-9071
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:High expression of nucleotide synthetic enzyme thymidylate synthase (TYMS) is responsible for the resistance to fluorouracil (FU) treatment and worse survival in colorectal cancer (CRC). Herein, we revealed that pleckstrin-2 (PLEK2) cooperated with YTHDF2 to enhance TYMS mRNA stability in CRC via an m 6 A dependent manner . Silencing of PLEK2 led to the degradation of TYMS mRNA that suppressed DNA replication, which activated p53/p21 signaling and consequent inhibition of CRC cell proliferation via the cellular senescence. Additionally, PLEK2 is also required for CRC cell migration, invasion and stemness-like properties. PLEK2 inhibition is sufficient to ameliorate the progression of AOM/DSS-induced CRC . Together, our study identified PLEK2 as a key regulator for the progress of CRC via the regulation of TYMS expression, and demonstrated that PLEK2 is a novel therapeutic target for CRC.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1420-9071
1420-682X
1420-9071
DOI:10.1007/s00018-025-05782-x